Medicines for Addiction

Adial is a biopharmaceutical company focused on the treatment and prevention of addictions and other unmet medical needs. We are in clinical and pre-clinical stages with multiple drug candidates including a genetically targeted therapeutic drug, AD04, for Alcohol Use Disorder (AUD) in Phase 3 and through our subsidiary, Purnovate, pre-clinical candidates including candidates for non-opioid pain management, and the treatment of metastatic breast cancer.

Managing Through Mixed Trial Results And An Economic Downturn

Ben Comer

Chief Editor, Life Science Leader

November 1, 2022

What would Jack Welch do? Cary Claiborne knows the answer from nearly 15 years working at GE and GE Capital, during a time that overlapped closely with Welch’s tenure as CEO. In August, Claiborne himself became CEO of Adial Pharma, a Charlottesville, VA-based biopharmaceutical company with a novel approach to treating alcohol use disorder (AUD). Claiborne faces several distinct challenges: mixed topline results from a Phase 3 trial of lead candidate AD04, the potential need to fund and conduct another trial prior to seeking regulatory approval, and managing the company through a difficult economic downturn. Lessons learned during formative work experiences at GE, the first place Claiborne worked after graduating from Rutgers University in 1982, have followed him through executive-level financial roles in industries including telecoms, retail, energy, renewable fuels, and biopharmaceuticals.

Read More


AUD is a significant disease that impacts over 35 million people, devastating human health, families, and economies. Current medications have severe side effects that cause compliance issues and limited effectiveness. We believe the market needs a drug like AD04 which, for our target population, may be highly effective with limited side effects. 

AD04 is specifically designed to:

  • Reduce drinking levels (believed through reduction of craving)
  • Potentially facilitate abstinence
  • Have limited side effects
  • Prove effective for patients testing for the companion genetic bio-marker (~33% of patients)
Learn More
Purnovate, Inc logo


Purnovate, Inc., a wholly-owned subsidiary of Adial Pharmaceuticals, has developed adenosine analogues that allow the creation of new medicines for inflammatory and neurotransmission-related diseases. These adenosine analogues are also a platform technology that amplifies and transform the effectiveness of medications for our partners.

We believe Purnovate has overcome the biodistribution challenges inherent in others’ previous selective adenosine analogs (e.g., lack of oral availability and tissue penetration).

Purnovate is developing novel selective adenosine analogs to treat serious diseases and disorders such as non-opioid pain management, asthma, cancer, wound healing, diabetes, cocaine addiction, and inflammatory indications.

Learn More